Careers  |  Sign In  |  Register

Single-Dose Anti-PD-1 Therapy Helps Predict Outcomes in Resectable Melanoma


Working with the theory that it would be possible to detect immune reinvigoration related to disease-free survival in various stages of melanoma, lead investigator Alexander C. Huang, MD, of the Department of Medicine, Perelman School of Medicine, at the University of Pennsylvania, Philadelphia, and colleagues, conducted a study of adjuvant/neoadjuvant anti–PD-1 therapy in patients with stage III/IV melanoma. “Pathological response and immunological analyses after a single neoadjuvant dose can be used to predict clinical outcome and to dissect underlying mechanisms in checkpoint blockade,” Huang concluded.

Learn more by clicking here.